Drugs / 177Lu-PSMA-0057
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06050239 | Mar 2023 → Mar 2025 | metastatic prostate carcinoma | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07310355 | Dec 2025 → Jun 2028 expected | castration-resistant prostate carcinoma | Chengdu StarRay Therapeutics Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-PSMA-0057 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07310355 ↗ |
| Modality | Other / unclassified | “177Lu-PSMA-0057 for radioligand therapy.” NCT07310355 ↗ |